A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Bococizumab; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.

• Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C greater than 100 mg/dL and fasting TG less than 400 mg/dL

Exclusion Criteria:

• History of a cardiovascular or cerebrovascular event or procedure during the past year.

• Poorly controlled type 1 or type 2 diabetes mellitus.

• Poorly controlled hypertension.